Status:
UNKNOWN
Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines
Lead Sponsor:
Guangzhou General Hospital of Guangzhou Military Command
Collaborating Sponsors:
Sun Yat-sen University
Conditions:
Cardiovascular Disease
Eligibility:
All Genders
30-60 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to confirm the protective effect and mechanism of anthocyanins on hyperuricemia patients with Cardiovascular disease.
Detailed Description
Hyperuricemia patients who have the ability to complete the intervention study in the early stage of study were selected as the research subjects. A randomized controlled double blind control method w...
Eligibility Criteria
Inclusion
- Serum uric acid \>420μmol/L (7mg/dL) in male, \>360μmol/L (6mg/dL) in female identified as hyperuricemia patients.
Exclusion
- Age more than 60 years and less than 30 years old;
- acute infection, tumor, recent surgery, need for hemodialysis and autoimmune diseases.
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
320 Patients enrolled
Trial Details
Trial ID
NCT02797028
Start Date
January 1 2015
End Date
December 1 2017
Last Update
June 13 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
General Hospital of Guangzhou Military Command of People's Liberation Army
Guangzhou, Guangdong, China, 020